Ocuphire Pharma, Inc. has completed its merger with Opus Genetics, issuing 5,237,063 shares of common stock and 14,145.374 shares of preferred stock, resulting in a pro forma cash balance of approximately $37 million as of September 30, 2024, with a cash runway expected into 2026. Following the merger, Ocuphire will change its name to Opus Genetics, Inc. on October 23, 2024.